Ralliant Corporation (NYSE:RAL) Sees Significant Drop in Short Interest

Ralliant Corporation (NYSE:RAL) was the target of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 3,692,056 shares, a decline of 35.5% from the July 30th total of 5,720,042 shares. Based on an average daily trading volume, of 1,479,843 shares, the days-to-cover ratio is presently 2.5 days. Currently, 3.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

RAL has been the topic of a number of analyst reports. BMO Capital Markets began coverage on Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 price target on the stock. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Royal Bank Of Canada upped their price objective on Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Oppenheimer raised their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley raised their price target on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant presently has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Stock Performance

Ralliant stock traded down $0.67 during trading hours on Tuesday, hitting $61.06. The company had a trading volume of 842,829 shares, compared to its average volume of 1,653,742. The firm has a market cap of $6.76 billion, a PE ratio of -5.63, a PEG ratio of 2.29 and a beta of 1.61. The firm has a 50-day moving average of $68.28 and a 200 day moving average of $56.66. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. Ralliant has a one year low of $37.27 and a one year high of $75.41.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, sell-side analysts expect that Ralliant will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.84%.

Insider Transactions at Ralliant

In other news, SVP Karen M. Bick sold 6,062 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the transaction, the senior vice president owned 31,668 shares of the company’s stock, valued at $2,280,096. This represents a 16.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $71.79, for a total transaction of $928,675.44. Following the transaction, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.42% of the company’s stock.

Institutional Trading of Ralliant

Institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LP lifted its holdings in shares of Ralliant by 41.2% in the second quarter. Corient Private Wealth LP now owns 35,050 shares of the company’s stock worth $2,581,000 after acquiring an additional 10,230 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Ralliant during the second quarter worth $3,634,000. California State Teachers Retirement System grew its position in shares of Ralliant by 7,051.8% in the 2nd quarter. California State Teachers Retirement System now owns 9,356,090 shares of the company’s stock valued at $688,889,000 after buying an additional 9,225,268 shares during the last quarter. Nykredit A S acquired a new stake in Ralliant during the 2nd quarter valued at approximately $219,000. Finally, B. Metzler seel. Sohn & Co. AG raised its stake in Ralliant by 231.8% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 23,944 shares of the company’s stock worth $1,763,000 after buying an additional 16,727 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.